ZAMBON SPA

The 'Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024' report highlights emerging therapies like Brensocatib and HSK31858, which aim to address the underlying mechanisms of NCFB, potentially improving patient quality of life. Key industry players are actively developing these therapies, with significant implications for managing NCFB.

Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.

Zambon announces Phase 3 PROMIS-I and PROMIS-II study results in The Lancet Respiratory Medicine, showing inhaled colistimethate sodium via I-neb reduced pulmonary exacerbations in Non-Cystic Fibrosis Bronchiectasis patients chronically colonized with P. aeruginosa.